Stay updated on Nivolumab and Ipilimumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab and Ipilimumab in Melanoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    A site-wide NIH banner announces a transition to using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI) across NIH content.
    Difference
    1%
    Check dated 2026-10-25T15:20:39.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-18T20:40:08.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.0 to v3.7.1. The page still displays a 403 error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T20:24:07.000Z thumbnail image
  4. Check
    38 days ago
    Change Detected
    Summary
    The page for the study now shows a 403 Forbidden error instead of the study details, indicating access restriction to the record and preventing viewing its information.
    Difference
    18%
    Check dated 2026-09-20T20:31:35.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The study's Israel location list was updated to add Tel Litwinsky and remove Qiryat Krinitzi, altering the set of participating sites. Additionally, Melanoma and the MedlinePlus Genetics related topic were added to the page's topics.
    Difference
    0.1%
    Check dated 2026-09-13T19:26:02.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    A new recruitment site in Qiryat Krinitzi, Israel, 52621 was added to the study's locations, expanding where participants can enroll. The Melanoma entry, related topics header, MedlinePlus Genetics link, and the Tel Litwinsky, Israel site were removed from the page.
    Difference
    0.1%
    Check dated 2026-09-06T22:27:00.000Z thumbnail image

Stay in the know with updates to Nivolumab and Ipilimumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab and Ipilimumab in Melanoma Clinical Trial page.